Introduction
Primary sarcomas comprise 0.8-2.7% of renal tumors in adults, of which up to 60% are leiomyosacromas. They affect women more commonly than men and affect the right kidney more frequently than the left. They often present with a classical triad of signs and symptoms including abdominal mass, flank pain and hematuria, clinically indistinguishable from renal cell carcinoma. They can occur at any age but are more common after the 5th decade of life [1] [2] [3] .
Primary renal leiomyosarcomas do not have radiological features to distinguish them from more common renal malignancies such as renal cell carcinoma, and although computed tomography (CT) remains the imaging modality of choice, the CT features of this rare tumor are non-specific. Magnetic resonance imaging (MRI) may be helpful in specific situations where venous thrombosis or vessel invasion by tumor are suspected [4] [5] [6] .
The use of 18 F-FDG PET/CT in the staging and followup of leiomyosarcomas is becoming well established and supported in the literature [7] [8] [9] [10] [11] . Its use in the management of primary renal leiomyosarcomas, however, has not been previously described. Renal leiomyosarcomas are very aggressive with poor long term outcomes. The role of adjuvant chemotherapy or radiotherapy has not been well established [12] [13] [14] . It is likely that 18 F-FDG PET/ CT will play a significant role in guiding the management of these rare tumors in the future.
Case Report
A 60 year old woman was diagnosed with a metastatic high grade leiomyosarcoma of unknown primary, after presenting with multiple small subcutaneous nodules in the upper back and upper arms. Two well circumscribed nodules, measuring 8 mm and 12 mm (excised from the upper back/right arm) showed markedly atypical smooth muscle proliferation, a proliferative index Ki-67 of 30%, and a mitotic score of 5 per 10 high power fields. She was referred for a staging 18 F-FDG PET/CT (Discovery ST, GE Healthcare, Waukesha, WI, USA) to search for the primary and determine the extent of the disease. Maximum intensity projection (MIP) images revealed multiple 18 F-FDG-avid subcutaneous nodules, the largest located in the left upper back measuring 2.2 cm with maximum standardized uptake value (SUV max ) of 1.9 ( Fig. 1 ), a lobulated 6 cm left renal solid mass with SUV max 9.7 ( Fig. 2) , and a 3.5 cm sacral mass with SUV max 11.1 (Fig. 3) . Additional imaging of the lower limbs was performed and showed a 2.5 cm mass in the right proximal tibia with SUV max 5.1 (Fig. 4) . The patient had not complained of any abdominal pain, or bone pain upon presentation.
Following the PET/CT imaging, the 6 cm 18 F-FDG avid left renal mass was biopsied, and histopathological evaluation confirmed a high grade primary renal leiomyosarcoma arising from the renal parenchyma (Fig. 5) . The patient received chemotherapy (three cycles of doxorubicin, ifosfamide, mesna) and palliative radiation therapy to the sacral and right tibial bone metastases (8 Gy in 1 fraction at each site).
A follow-up 18 F-FDG PET/CT was performed 1 year after the staging PET/CT to assess the response to chemotherapy and radiation therapy. PET/CT MIP images showed that the left upper back lesion seen in Fig. 3 responded completely to chemotherapy. The left renal mass SUV max increased from 9.7 to 11.6, while the sacral lesion metabolism did not change significantly (SUV max F-FDG left renal mass (left arrow) which was histologically confirmed to be a primary renal leiomyosarcoma 10.4, from previous SUV max 11.1). The right proximal tibial lesion was slightly larger in size but showed no change in SUV max (4.6 from previously 5.1). There was a new bone metastasis in the right proximal humerus with SUV max 3.1 as well as multiple new subcutaneous metastases in both thighs, consistent with progression of metastatic disease (Fig. 6 ).
Discussion
Primary sarcomas of the kidney account for 1-2% of all malignant renal tumors in adults, and leiomyosarcoma accounts for 50-60% of these. Primary renal leiomyosarcoma may arise from the smooth muscle fibers of the renal parenchyma (as in this case), renal capsule, renal pelvis or renal vessels. The mean patient age at diagnosis is 58.5 years and it affects women more commonly with a ratio of 3:2. Patients usually present with flank pain and an abdominal mass, with or without hematuria, and occasionally spontaneous rupture and severe peri-renal haemorrhage. The right kidney is affected approximately 60% of the time [1, 2] .
Renal leiomyosarcoma presents a diagnostic challenge, because there are no reliable clinical or radiological features to distinguish it from more common renal malignancies such as renal cell carcinoma, and histological evaluation is the only way to truly establish the diagnosis. These tumors can present as solid or cystic masses and neither ultrasonography, CT, nor MRI are able to differentiate renal leiomyosarcomas from renal cell carcinomas or other more common renal tumors [3] [4] [5] . MRI may be useful in very specific cases to assess for inferior vena cava thrombosis or tumor invasion of vessels [6] .
18 F-FDG PET/CT is routinely used in the staging and follow-up of therapy of leiomyosarcomas, although it cannot differentiate low grade leiomyosarcomas from benign soft tissue tumors [7] [8] [9] [10] [11] . The use of 18 F-FDG PET/CT in the evaluation of primary leiomyosarcoma of the kidney has not been previously described in the literature. Renal leiomyosarcomas are considered to be very aggressive due to their rapid growth rate, frequent metastases, and high rate of tumor recurrence. Five year survival is less than 25% and median survival ranges from 1.5 to 2 years [1] . Radical nephrectomy offers the best chance for cure and the role of adjuvant chemotherapy or radiotherapy has not yet been established [12] [13] [14] . In this rare case, 18 F-FDG PET/CT was useful in identifying the location of the primary metastatic leiomyosarcoma of unknown origin and a post therapy PET/CT was able to assess response to chemotherapy and radiation therapy, and confirm overall progression of metastatic disease.
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